西大门：10月24日召开董事会会议

Group 1 - The core point of the article is that Xidamen (SH 605155) held its fourth board meeting on October 24, 2025, to discuss the management system for senior executives' departure [1] - For the year 2024, Xidamen's revenue composition is as follows: 57.11% from sunshade fabric manufacturing, 39.72% from sunshade finished products manufacturing, 2.02% from other manufacturing, and 1.14% from other businesses [1] - As of the report, Xidamen has a market capitalization of 2.9 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have generated $80 billion in overseas licensing this year, highlighting a contrast between the hot secondary market and the cold fundraising environment in the primary market for the biopharmaceutical sector [1]